Acute Myeloid Leukemia | Unmet Need | US/EU | 2018

Acute myeloid leukemia (AML) is the most common and aggressive form of leukemia in adults, with the lowest survival rates of all blood cancer types. Despite significant advances in understanding the disease, current treatment is dominated by chemotherapeutic agents offering limited efficacy benefits, after which recurrence is almost guaranteed. After years of dormancy and high levels of unmet need, four new drug approvals in 2017—Rydapt (Novartis), Idhifa (Celgene/Agios Pharmaceuticals), Mylotarg (Pfizer), and Vyxeos (Jazz Pharmaceuticals)—are expected to transform the way AML is treated. We assess how current therapies perform on key drug attributes and measure the impact of attributes on physicians’ prescribing behavior. We also consider which unmet needs novel therapies should address to distinguish themselves from their rivals and maximize uptake.


  • What are the treatment drivers and goals for AML? What impact does duration of response and event-free survival rates have on prescribing decisions in AML?
  • How do current therapies, such as Celgene’s Vidaza and Otsuka/Janssen’s Dacogen, and other chemotherapy regimens perform on key clinical drug attributes for this indication?
  • What are the prevailing areas of unmet need and opportunity in first-line, older AML patients? Are late-phase emerging therapies targeting these areas?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European oncologists for a new treatment for first-line, older AML patients?


Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.


United States, France, Germany, United Kingdom


Survey of 60 hematologist-oncologists in U.S. and 30 hematologists in Europe


Dacogen, gilteritinib, guadecitabine, Mylotarg, Venclexta/Venclyxto, Vidaza, quizartinib


  • Stated versus derived analysis of U.S. and European physician prescribing behavior.
  • Conjoint analysis with U.S. and European physicians; includes market simulator.
  • Assessment of current drug performance against treatment drivers and goals.
  • Physician perceptions of unmet need in subpopulation covered.
  • Analysis of remaining drug development opportunities.
Login to access report